Growth inhibition of medullary thyroid carcinoma cells by pyrazolo-pyrimidine derivates

Journal of Endocrinological Investigation

Volumn 30, Issue 10, 2007, Pages

  Morisi, R ^a   Celano, M ^b   Tosi, E ^a   Schenone, S ^c   Navarra, M ^d   Ferretti, E ^a   Costante, G ^b   Durante, C ^a   Botta, G ^e   D'Agostino, M ^b   Brullo, C ^c   Filetti, S ^a   Botta, M ^e   Russo, D ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d IRCCS CENTRO NEUROLESI BONINO PULEJO   (Italy)

^e UNIVERSITY OF SIENA   (Italy)

Author keywords

Medullary thyroid cancer; MZ CRC I cells; Pyrazolopyrimidines; RET; TT cells

Indexed keywords

CYSTINE; DRUG VEHICLE; METHIONINE; N BENZYL 1 (2 CHLORO 2 PHENYLETHYL) 6 (METHYLTIO) 1H PYRAZOLO[3,4 D]PYRIMIDIN 4 AMINE; PROTEIN RET; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; PYRAZOLOPYRIMIDINE DERIVATIVE; SI 34; THREONINE; TRYPTOPHAN; UNCLASSIFIED DRUG; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; RET PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; BIOCHEMISTRY; CANCER CELL CULTURE; CELL DEATH; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; DRUG RESPONSE; DRUG SENSITIVITY; ENZYME ACTIVITY; GENE MUTATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VIVO STUDY; INCUBATION TIME; MORTALITY; SIPPLE SYNDROME; THYROID MEDULLARY CARCINOMA; CELL DIVISION; DRUG ANTAGONISM; DRUG EFFECT; MEDULLARY CARCINOMA; METABOLISM; MULTIPLE ENDOCRINE NEOPLASIA; PATHOLOGY; THYROID TUMOR; TUMOR CELL LINE; TUMOR RECURRENCE;

APOPTOSIS; CARCINOMA, MEDULLARY; CELL DIVISION; CELL LINE, TUMOR; HUMANS; MULTIPLE ENDOCRINE NEOPLASIA TYPE 1; NEOPLASM RECURRENCE, LOCAL; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-RET; PYRAZOLES; PYRIMIDINES; THYROID NEOPLASMS;

EID: 38449096470     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03349220     Document Type: Article

References (17)

1. Leboulleux S, Baudin E, Travagli JP, Schlumberger M. Medullary thyroid carcinoma. Clin Endocrinol (Oxf) 2004, 61: 299-310.
2. Massoll N, Mazzaferri EL. Diagnosis and management of medullary thyroid carcinoma. Clin Lab Med 2004, 24: 49-83.
3. de Groat JW, Links TP, Plukker JT, Lips CJ, Hofstra RM. RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors. Endocr Rev 2006, 27: 535-60.
4. Santoro M, Carlomagno F. Drug insight: Small-molecule inhibitors of protein kinases in the treatment of thyroid cancer. Nat Clin Pract Endocrinol Metab 2006, 2: 42-52.
5. Drosten M, Putzer BM. Mechanisms of Disease: cancer targeting and the impact of oncogenic RET for medullary thyroid carcinoma therapy. Nat Clin Pract Oncol 2006, 3: 564-74.
6. Carlomagno F, Vitagliano D, Guida T et al. The kinase inhibitor PPI blocks tumorigenesis induced by RET oncogenes. Cancer Res 2002, 62: 1077-82.
7. Carniti C, Perego C, Mondellini P, Pienotti MA, Bongarzone I. PPI inhibitor induces degradation of RET-MEN2A and RET-MEN2B oncoproteins through proteosomal targeting. Cancer Res 2003, 63: 2234-43.
8. Carlomagno F, Vitagliano D, Guida T, et al. Efficient inhibition of RET/ papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2). J Clin Endocrinol Metab 2003, 88: 1897-902.
9. Liu Z, Falola J, Zhu X, et al. Antiproliferative effects of Src inhibition on medullary thyroid cancer. J Clin Endocrinol Metab 2004, 89: 3503-9.
10. Schenone S, Bruno O, Ranise A, et al. New pyrazolo[3,4-d]pyrimidines endowed with A431 antiproliferative activity and inhibitory properties of Src phosphorylation. Bioorg Med Chem Lett 2004, 14: 2511-7.
11. Carraro F, Pucci A, Naldini A, et al. Pyrazolo(3,4-d]pyrimidines endowed with antiproliferative activity on ductal infiltrating carcinoma cells. J Med Chem 2004, 47: 1595-8.
12. Cooley LD, Elder FF, Knuth A, Gagel RF. Cytogenetic characterization of three human and three rat medullary thyroid carcinoma cell lines. Cancer Genet Cytogenet 1995, 80: 138-49.
13. Carlomagno F, Salvatore D, Santoro M, et al. Point mutation of the RET proto-oncogene in the TT human medullary thyroid carcinoma cell line. Biochem Biophys Res Commun 1995, 207: 1022-8.
14. Celano M, Calvagno MG, Bulotta S, et al. Cytotoxic effects of gemcitabine-loaded liposomes in human anaplastic thyroid carcinoma cells. BMC Cancer 2004, 4: 63.
15. Russo D, Bisca A, Celano M, et al. Proteomic analysis of human thyroid cell lines reveals reduced nuclear localization of Mn-SOD in poorly differentiated thyroid cancer cells. J Endocrinol Invest 2005, 28: 137-44.
16. Bjorge JD, Jakymiw A, Fujita DJ. Selected glimpses into the activation and function of Src kinase. Oncogene 2000, 19: 5620-35.
17. Melillo RM, Barone MV, Lupoli G, et al. Ret-mediated mitogenenis requires Src kinase activity. Cancer Res 1999, 59: 1120-6.